Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines

Fulya Ustun-Alkan; Tülay Bakırel; Oya Üstüner; Ceren Anlas; Suzan Cinar; Funda Yıldırım; Aydın Gürel

doi:10.2478/jvetres-2021-042

Abstract

Introduction

Masitinib mesylate, a selective tyrosine kinase inhibitor of the c-KIT receptor, is used for the treatment of mast cell tumours in dogs. Masitinib has previously been investigated in various cancers; however, its potential anticancer effect in canine mammary tumours (CMTs) is unknown. In the present paper, we investigated the antiproliferative effect of masitinib in CMT cells and its possible mechanisms of action.

Material and Methods

The effect of masitinib on the proliferation of CMT-U27 and CMT-U309 cells was assessed by MTT assay and DNA fragmentation. Flow cytometric analysis was used to measure the effect of masitinib on apoptosis and the cell cycle. Additionally, vascular endothelial growth factor levels (VEGF) were measured, and the proliferation marker Ki-67 was visualised in immunocytochemical stainings in CMT cells.

Results

Treatment with masitinib inhibited the proliferation of CMT cells in a concentration-dependent manner. Maximal apoptotic activity and DNA fragmentation were observed at approximately IC₅₀ of masitinib in both cell lines. In addition, cell cycle distribution was altered and VEGF levels and Ki-67 proliferation indices were decreased in masitinib-treated cells in comparison with control cells.

Conclusion

In this study, masitinib suppressed cell proliferation concomitantly via induction of apoptosis and cell cycle arrest by decreasing VEGF levels and the Ki-67 proliferation index in CMT-U27 and CMT-U309 cells in vitro, suggesting its potential as a therapeutic tool in the clinical setting of mammary cancer treatment in dogs.

References

Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore, L., Thome M., Christie A.L., Murakami M.A., Michielin O., Ciriello, G., Zoete V., Oricchio E.: Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood 2018, 131, 2345–2356, doi: 10.1182/blood-2017-10-809210.
Open DOI Search in Google Scholar Back to article
Bavcar S., Argyle D.J.: Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Vet Comp Oncol 2012, 10, 163–173, doi: 10.1111/j.1476-5829.2012.00342.x.
Open DOI Search in Google Scholar Back to article
Chang C.Y., Chiou P.P., Chen W.J., Li Y.H., Yiu J.C., Cheng Y.H., Chen S.D., Lin C.T., Lai Y.S.: Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines. Res Vet Sci 2010, 88, 285–293, doi: 10.1016/j.rvsc.2009.08.006.
Open DOI Search in Google Scholar Back to article
Ciardiello F., Tortora G.: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7, 2958–2970.
Search in Google Scholar Back to article
Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Castéran N., Borge L., Hajem B., Lermet A., Sippl W., Voisset E., Arock M., Auclair C., Leventhal P.S., Mansfield C.D., Moussy A., Hermine O.: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS One 2009, 4, e7258, doi: 10.1371/journal.pone.0007258.
Open DOI Search in Google Scholar Back to article
Fahey C.E., Milner R.J., Kow K., Bacon N.J., Salute M.E.: Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anti-Cancer Drugs 2013, 24, 519–526, doi: 10.1097/CAD.0b013e32836002ba.
Open DOI Search in Google Scholar Back to article
Hahn K.A., Oglivie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O.: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008, 22, 1301–1309, doi: 10.1111/j.1939-1676.2008.0190.x.
Open DOI Search in Google Scholar Back to article
Holtermann N., Kiupel M., Kessler M., Teske E., Betz D., Hirschberger J.: Masitinib monotherapy in canine epitheliotropic lymphoma. Vet Comp Oncol 2016, 14, 127–135, doi: 10.1111/ vco.12157.
Open DOI Search in Google Scholar Back to article
Karayannopoulou M., Lafioniatis S.: Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Revue Méd Vét 2016, 167, 192–200.
Search in Google Scholar Back to article
Kaszak I., Ruszczak A., Kanafa S., Kacprzak K., Król M., Jurka P.: Current biomarkers of canine mammary tumors. Acta Vet Scand 2018, 60, 66, doi: 10.1186/s13028-018-0417-1.
Open DOI Search in Google Scholar Back to article
Kato Y., Asano K., Mogi T., Kutara K., Teshima K., Edamura K., Tsumagari S., Hasegawa A., Tanaka S.: Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors. J Vet Med Sci 2007, 69, 77–80, doi: 10.1292/jvms.69.77.
Open DOI Search in Google Scholar Back to article
Koltai Z., Szabó B., Jakus J., Vajdovich P.: Tyrosine kinase expression analyses in canine mammary gland tumours – A pilot study. Acta Vet Hung 2018, 66, 294–308, doi: 10.1556/004.2018.027.
Open DOI Search in Google Scholar Back to article
Kubo K., Matsuyama S., Katayama K., Tsutsumi C., Yonezawa K., Shimada T., Kotani T., Sakuma S., Ohashi F., Takamori Y.: Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. J Vet Med Sci 1998, 60, 1335–1340, doi: 10.1292/jvms.60.1335.
Open DOI Search in Google Scholar Back to article
Lawrence J., Saba C., Gogal Jr R., Lamberth O., Vandenplas M.L., Hurley D.J., Dubreuil P., Hermine O., Dobbin K., Turek M.: Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells. Vet Comp Oncol 2012, 10, 143–154, doi: 10.1111/j.1476-5829.2011.00291.x.
Open DOI Search in Google Scholar Back to article
Lyles S.E., Milner R.J., Kow K., Salute M.E.: In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 2012, 10, 223–235, doi: 10.1111/j.1476-5829.2012.00335.x.
Open DOI Search in Google Scholar Back to article
Marech I., Patruno R., Zizzo N., Gadaleta C., Introna M., Zito A.F., Gadaleta C.D., Ranieri G.: Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 2014, 91, 98–111, doi: 10.1016/j.critrevonc.2013.12.011.
Open DOI Search in Google Scholar Back to article
Michishita M., Ohtsuka A., Nakahira R., Tajima T., Nakagawa T., Sasaki N., Arai T., Takahashi K.: Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma. J Vet Med Sci 2016, 78, 685–694, doi: 10.1292/jvms.15-0550.
Open DOI Search in Google Scholar Back to article
Milovancev M., Helfand S.C., Marley K., Goodall C.P., Löhr C.V., Bracha S.: Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Vet Res 2016, 12, 85, doi: 10.1186/s12917-016-0712-x.
Open DOI Search in Google Scholar Back to article
Pena L.L., Nieto A.I., Pérez-Alenza D., Cuesta P., Castano M.: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998, 10, 237–246, doi: 10.1177/104063879801000303.
Open DOI Search in Google Scholar Back to article
Queiroga F.L., Raposo T., Carvalho M.I., Prada J., Pires I.: Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 2011, 25, 455–465.
Search in Google Scholar Back to article
Ranieri G., Gadaleta C.D., Patruno R., Zizzo N., Daidone M.G., Hansson M.G., Paradiso A., Ribatti D.: A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013, 88, 187–197, doi: 10.1016/j.critrevonc.2013.03.005.
Open DOI Search in Google Scholar Back to article
Restucci B., Papparella S., Maiolino P., De Vico G.: Expression of vascular endothelial growth factor in canine mammary tumors. Vet Pathol 2002, 39, 488–493, doi: 10.1354/vp.39-4-488.
Open DOI Search in Google Scholar Back to article
Sandström M., Johansson M., Andersson U., Bergh A., Bergenheim A.T., Henriksson R.: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 2004, 91, 1174–1180, doi: 10.1038/sj.bjc.6602108.
Open DOI Search in Google Scholar Back to article
Scholzen T., Gerdes J.: The Ki‐67 protein: from the known and the unknown. J Cell Physiol 2000, 182, 311–322, doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.
Open DOI Search in Google Scholar Back to article
Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M.: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non–small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65, 1459–1470, doi: 10.1158/0008-5472.CAN-04-1872.
Open DOI Search in Google Scholar Back to article
Thamm D.H., Rose B., Kow K., Humbert M., Mansfield C.D., Moussy A., Hermine O., Dubreuil P.: Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Vet J 2012, 191, 131–134, doi: 10.1016/j.tvjl.2011.01.001.
Open DOI Search in Google Scholar Back to article
Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M.: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7, 3129–3140, doi: 10.1158/1535-7163.MCT-08-0013.
Open DOI Search in Google Scholar Back to article
Wolfesberger B., Tonar Z., Gerner W., Skalicky M., Heiduschka G., Egerbacher M., Thalhammer J.G., Walter I.: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 2010, 88, 94–100, doi: 10.1016/j.rvsc.2009.06.009.
Open DOI Search in Google Scholar Back to article
Xiao X., Wu J., Zhu X., Zhao P., Zhou J., Liu Q.Q., Zheng L., Zeng M., Liu R., Huang W.: Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007, 121, 2095–2104, doi: 10.1002/ijc.22955.
Open DOI Search in Google Scholar Back to article
Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., Sun Y., Han X.: Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat Rec (Hoboken) 2009, 292, 1122–1127, doi: 10.1002/ar.20938.
Open DOI Search in Google Scholar Back to article